Amanda L Baer
Overview
Explore the profile of Amanda L Baer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
66
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Millar J, Lassman M, Thomas T, Ramakrishnan R, Jumes P, Dunbar R, et al.
J Lipid Res
. 2017 Mar;
58(6):1214-1220.
PMID: 28314859
Cholesteryl ester transfer protein (CETP) mediates the transfer of HDL cholesteryl esters for triglyceride (TG) in VLDL/LDL. CETP inhibition, with anacetrapib, increases HDL-cholesterol, reduces LDL-cholesterol, and lowers TG levels. This...
2.
Millar J, Reyes-Soffer G, Jumes P, Dunbar R, deGoma E, Baer A, et al.
J Clin Invest
. 2016 Apr;
126(4):1603-4.
PMID: 27035815
No abstract available.
3.
Reyes-Soffer G, Millar J, Ngai C, Jumes P, Coromilas E, Asztalos B, et al.
Arterioscler Thromb Vasc Biol
. 2016 Mar;
36(5):994-1002.
PMID: 26966279
Objective: Anacetrapib (ANA), an inhibitor of cholesteryl ester transfer protein (CETP) activity, increases plasma concentrations of high-density lipoprotein cholesterol (HDL-C), apolipoprotein A-I (apoA)-I, apoA-II, and CETP. The mechanisms responsible for...
4.
Millar J, Reyes-Soffer G, Jumes P, Dunbar R, deGoma E, Baer A, et al.
J Clin Invest
. 2015 May;
125(6):2510-22.
PMID: 25961461
Background: Individuals treated with the cholesteryl ester transfer protein (CETP) inhibitor anacetrapib exhibit a reduction in both LDL cholesterol and apolipoprotein B (ApoB) in response to monotherapy or combination therapy...
5.
Raper A, Kolansky D, Sachais B, Meagher E, Baer A, Cuchel M
J Clin Lipidol
. 2015 Feb;
9(1):107-12.
PMID: 25670368
We report the case of a 49-year-old woman with homozygous familial hypercholesterolemia and a complicated cardiovascular history, treated for 5 years with a microsomal triglyceride transfer protein inhibitor in addition...